CD19 and precursor B-cell acute lymphoblastic leukemia: Brexucabtagene autoleucel, an autologous CD19/CD28/CD3z CAR-T, showed equally robust clinical data in the phase II ZUMA-3 trial which evaluated its safety and efficacy in relapsed/refractory B-ALL [54].